Clostridioides difficile is an anaerobic gram-positive bacterium that can can produce the large 22 clostridial toxins, Toxin A and Toxin B, encoded within the pathogenicity locus (PaLoc). The PaLoc also 23 encodes the sigma factor TcdR, that positively regulates toxin gene expression, and TcdC, a putative 24 negative regulator of toxin expression. TcdC is proposed to be an anti-sigma factor, however, several 25 studies failed to show an association between tcdC genotype and toxin production. Consequently, TcdC 26 function is not yet fully understood. Previous studies have characterized TcdC as a membrane-associated 27 protein with the ability to bind G-quadruplex structures. The binding to the DNA secondary structures is 28 mediated through the OB-fold domain present at the C-terminus of the protein. This domain was 29 previously also proposed to be responsible for the inhibitory effect on toxin gene expression, implicating 30 a cytoplasmic localization of the C-terminal OB-fold.
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31
In this study we aimed to obtain topological information on the C-terminus of TcdC. Using Scanning 32 Cysteine Accessibility Mutagenesis and a HiBiT-based system, we demonstrate that the C-terminus of 33 TcdC is located extracellularly. The extracellular location of TcdC is not compatible with direct binding of 34 the OB-fold domain to intracellular nucleic acid or protein targets, and suggests a mechanism of action 35 that is different from characterized anti-sigma factors.
36
Introduction 48
Clostridioides difficile (Clostridium difficile) (1) is an opportunistic pathogen that can cause 49 disease in individuals with dysbiosis of the gut microbiota (2). Clostridium difficile infection (CDI) incidence 50 has increased worldwide and leads to a broad spectrum of symptoms, from mild diarrhea to toxin 51 megacolon, and even death (3).
52
Several factors contribute to the progression and the severity of CDI (2, 4) . C. difficile is a Gram-53 positive anaerobic bacterium that has the ability to form spores, which allows for dissemination and 54 colonization (2). The main virulence factors are the large clostridial toxins that induce damage to the 55 epithelial cells and lead to an inflammatory response that underlies the symptoms of CDI (2, 3, 5).
56
C. difficile strains have been found to produce up to three toxins: Toxin A (TcdA), Toxin B (TcdB) 57 and binary toxin (CDT) (5, 6) . Toxins A and B are encoded by genes tcdA and tcdB, respectively, located on 58 a 19.6 kb chromosomal region termed pathogenicity locus (PaLoc) (7) . TcdA and TcdB are 59 glucosyltransferases and once translocated to the cytosol of the intestinal epithelial cells, start a cascade 60 of events that can eventually lead to cell death (2, 5) . CDT, encoded by the cdtA and ctdB genes, is an ADP-61 ribosylating toxin that acts on the actin cytoskeleton (8).
62
The PaLoc contains at least 3 additional genes that appear to be involved in the regulation of the 63 expression or function of the large clostridial toxins: tcdE, tcdR and tcdC (5, 6) . TcdE is a putative holin-like 64 protein, thought to be involved in toxin secretion, however its exact role is still unclear (9). TcdR is an RNA 65 polymerase sigma factor that acts as the positive transcriptional regulator of tcdA, tcdB and tcdE and also 66 positively regulates its own expression. A direct interaction between TcdR and RNA polymerase allows 67 the recognition of the target promoters and activates expression (5, 10) . Expression of tcdR, and 68 consequently tcdA and tcdB, is influenced by different stimuli, such as temperature, nutrient availability 69 and medium composition (11) (12) (13) (14) .
70
Analysis of gene transcription by quantitative PCR has shown that while the expression of tcdA, 71 tcdB, tcdE and tcdR is low during exponential phase, these strongly increase upon entering stationary 72 phase. In contrast, tcdC was found to be highly expressed during exponential phase but to decrease in 73 stationary phase (15). Similar profiles were shown at the protein level, where levels of TcdC were higher 74 in the exponential growth phase (16). Together, these data suggested that TcdC might act as a negative 75 regulator of toxin transcription. However, several other studies did not find a decrease in tcdC 76 transcription in stationary phase and but rather showed a constant expression level during the stationary 77 growth phase (14, 17, 18) .
78
Likewise, the association between toxin expression and tcdC gene variants is subject of debate.
79
Increased virulence in epidemic strains was thought to be caused by deletions and frameshift mutations 80 in tcdC, leading to a severely truncated non-functional protein and presumably higher toxin titers as a 81 consequence (19, 20) . In support of this, it was shown that introduction of a plasmid-based copy of the 82 wild type tcdC gene in strain M7404 (PCR ribotype 027, carrying a truncated tcdC) resulted in decreased 83 virulence in hamsters (20) . However, mutations in the tcdC gene of clinical isolates did not predict the 84 activity of toxins A and B (18, 21) . Moreover, several studies failed to observe a relation between toxin 85 gene expression and tcdC genotype. Restoration of chromosomal tcdC of outbreak strain R20291 (PCR 86 ribotype 027) to wild type did not result in altered toxin expression (22) and toxin expression in C. difficile 87 630erm and an isogenic tcdC clostron mutant showed no significant differences observed in toxin levels 88 (17) .
89
Previous studies have characterized the domain structure of TcdC (16, 23) . TcdC is a 26 kDa 90 dimeric protein that contains an N-terminal transmembrane region (residues 30-50), that allows its 91 anchoring to the cell membrane, a coiled-coil dimerization domain and a C-terminal functional domain 92 (10, 23 
103
It is clear that further studies are required to understand TcdC binding partners and their function 104 in transcriptional repression. The prevailing model is that TcdC functions as an anti-sigma factor, whose 105 6 activity depends on cytosolic localization of the C-terminal OB-fold domain. However, the topological 106 information of the C-terminal domain has not been demonstrated to date.
107
In this study, we aimed to determine whether the C-terminal domain of TcdC is cytosolic or 108 surface exposed. Using different topology prediction methods, Substituted Cysteine Accessibility Method 109 (SCAM) and a codon-optimized version of the HiBiT Extracellular Detection System (HiBiT opt ), we find that 
128
We also investigated the presence of a potential signal peptide in the TcdC amino acid sequence 129 through SignalP 5.0 (26). However, no known signal peptide was identified, suggesting TcdC remains 130 tethered to the membrane (Fig. 1C ).
131
Though the reliability of the predictions is relatively low, both TMHMM and TOPCONS support 132 the presence of the transmembrane helix ( Fig.1 ), consistent with previous observations (10, 16).
133
Strikingly, both methods suggest that the TcdC C-terminus is located outside of the cell. As this would be 134 incompatible with a role for the OB-fold domain in sequestering TcdR or repression of TcdR-mediated 135 transcriptional activation, we set out to obtain topological information on the OB-fold domain in C. 
146
A typical SCAM experiment relies on immunoprecipitation of protein (using antibody specific for 147 the protein of interest), detection of immunoprecipitated protein (using a second antibody, directed at a 148 tag on the protein of interest), and verification of labelling with the MPB (using anti-biotin antibodies).
149
We introduced a C-terminally 3xmyc-tagged TcdC construct (TcdC-3xmyc), under the control of the 150 inducible promoter Ptet (28), that can be precipitated with anti-TcdC (α-TcdC) antibody and detected using 151 anti-myc antibodies (α-myc). We affinity purified a previously generated TcdC antibody (17) and verified 152 its specificity on C. difficile lysates by immunoblotting. The TcdC-3xmyc construct was induced and 153 samples before and after induction were analyzed. Only in the induced samples a band migrating at the 154 approximate molecular weight of TcdC was observed (38 kDa, Fig. 2A ), suggesting that native levels of 155 TcdC under non-inducing conditions are below our limit of detection in this assay. Though the predicted 156 molecular weight of the TcdC protein is 23 kDa, a higher molecular weight on SDS-PAGE has been observed 157 before of approximately 37 kDa (10, 23). Several bands were detected with a lower molecular weight than 158 expected ( Fig. 2A ). The fact that these are only present when TcdC-3xmyc is induced ( 
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TcdC contains 2 endogenous cysteines; one at position 51, right after the predicted 162 transmembrane domain (residues 30 to 50) and another one at position 184, located in the predicted OB-163 fold (Fig. 2B ). To evaluate the cysteine labelling on the native protein, we assessed biotinylation of TcdC-164 3xmyc (Fig. 1C ). The signal in the anti-biotin (α-biotin) Western blot suggests that one, or both, of the 165 native cysteine residues in TcdC-3xmyc is accessible for labelling by MPB. To delineate which of the two 166 cysteine residues (C51 and C184) contributes to the signal, we constructed a TcdC mutant in which one 167 cysteine residue is changed into a serine residue. Mutation of C51 (TcdC(C51S)-3xmyc) resulted in loss of 168 biotinylation in the presence of MPB (Fig. 1C ), despite the fact that C184 was still present, suggesting that 169 it is C51 that is biotinylated in TcdC-3xmyc. The lack of signal was not due to poor expression of the 170 protein, as the signal in the anti-myc Western blot is comparable to the TcdC-3xmyc protein.
As both native cysteines were predicted to be outside of the cell (Fig. 1, Fig. 2B ), we expected 172 biotinylation of C184 in the C51S mutant. Careful investigation of the predicted OB-fold structure (Fig. 2D) 173 suggested that C184 was buried in the OB fold, inaccessible for biotinylation. To determine if a failure to 174 biotinylate is not a general feature of the OB-fold domain, we then introduced a cysteine in TcdC(C51S)-175 3xmyc at position 175 (TcdC(C51S/S175C)-3xmyc), located in a predicted surface exposed loop ( Fig. 2D ).
176
We found that TcdC(C51S/S175C)-3xmyc was efficiently biotinylated in the presence of MPB, despite 177 lower expression than the TcdC-3xmyc ( Fig 2C) , showing the extracellular localization of the TcdC OB-fold.
178
Together, the SCAM experiments suggest that C51 and the OB-fold (C175) are located 179 extracellularly. We sought to confirm these results in an independent assay. The importance of TcdC for regulation of toxin expression is highly controversial. Though the 227 prevailing model suggests that TcdC is an anti-sigma factor with a role as a negative regulator of toxin 228 transcription (19, 20) , several other studies have found no clear relation between TcdC expression and 229 the toxin levels (17, 18, 21, 22) . Previous biochemical analyses of TcdC revealed that it is membrane-230 associated and that the C-terminus of TcdC comprises a dimerization domain and a domain with a 231 predicted OB-fold, that is important for transcriptional repression (10). However, the localization of the 232 C-terminus of TcdC has not been studied to date and this was addressed in the present study. Three 233 independent lines of evidence suggest an extracellular location for the OB-fold domain of TcdC.
234
In silico analyses of the TcdC amino acid sequence using TMHMM 2.0 (24), TOPCONS (25), and 235 SignalP 5.0 (26) suggest the presence of a transmembrane helix, but predicts no high-probability cleavage 236 as expected for a secretion signal for any of the canonical secretion pathways (Fig. 1) . The prediction of a 237 transmembrane domain is consistent with the previously described biochemical assays demonstrating 238 association of TcdC with the C. difficile membrane (16, 23). Analysis did not reach consensus on the 239 localization of the N-terminus, due to low reliability scores and differences obtained with the prediction 240 methods (Fig. 1) . Nevertheless, both TMHMM 2.0 and TOPCONS suggest that the C-terminus of TcdC 241 (residues 50 to 232, Fig. 1) is located on the outside of the cell. The in silico predictions are supported by 242 the results of the Scanning Cysteine Accessibility Method (SCAM) and the HiBiT opt experiments.
243
For the SCAM experiments we took advantage of the 2 cysteine residues that are natively present 244 after the transmembrane helix of TcdC. Biotin labelling of TcdC-3xmyc was detected, suggesting one or 245 both of the native cysteine residues are accessible for labelling by MPB (27) and located in the extracellular 246 environment (Fig. 2C) . TcdC(C51S)-3xmyc did not show any MBP labelling (Fig. 2C) although it contains 247 the cysteine at position 184, in the 4 th ß-sheet of the OB-fold domain. The compact fold of this domain 248 might interfere with MPB labelling, though we cannot exclude other reasons. As TcdC-3xmyc labelling was 249 solely due to the presence of the native cysteine 51, downstream of the predicted transmembrane 250 domain ( Fig. 1 and 2B ) and we were interested in validating the location of the OB-fold domain, we used 251 the sequence of TcdC(C51S)-3xmyc as a template to introduce a cysteine residue at position 175. The 252 native serine at position 175 is located in a loop connecting ß-sheet 3 and 4 in the OB-fold and predicted 253 to be solvent exposed, making this position an ideal candidate for MPB labeling (Fig. 2) . When expressing 254 TcdC(C51S/S175C)-3xmyc, efficient labeling was observed, indicating that lack of labelling is not a generic 255 feature of the OB-fold and supporting the extracellular location of the TcdC C-terminus (Fig. 2C) . We note 256 that the pattern of labelling is different between the TcdC-3xmyc and TcdC(C51S/S175C)-3xmyc. We do 257 not know the nature of these differences, but as all bands appear to run at a higher molecular weight than 258 expected from the theoretical mass of TcdC (as also observed by others (10, 23) 
264
Nevertheless, our results are confirmed in independent experiments using the HiBiT opt system, which to 265 our knowledge, is applied for the first time in C. difficile here and extends our existing luciferase toolkit 266 (29, 30) .
267
Our finding that the TcdC C-terminus is extracellular challenges the prevailing model of TcdC as 268 an anti-sigma factor. Anti-sigma factors generally sequester their cognate sigma factors away from RNAP 269 using substantial cytoplasmic domains (38). The small N-terminal sequence, that may or may not be 270 intracellular, is not likely to fulfill this function. Our experiments clearly place the C-terminal domain, that 271 previously was postulated to be responsible for transcriptional repression (10), in a different environment 272 than TcdR and RNAP. One has to wonder whether the OB-fold would ever be in contact with these 273 proteins, as was demonstrated in experiments using purified proteins (outside the context of a C. difficile 274 cell) and in heterologous expression systems (10). It should be noted that an extracellular location of TcdC 275 does not exclude a function as a negative regulator of toxin production, but if so, suggests that it does so 276 through an indirect mechanism.
277
Our data rather implies binding of OB-fold to an extracellular ligand. Bacterial OB-fold proteins 278 have been identified in bacterial genomes and can bind a wide variety of molecules (39, 40). Thus, TcdC 279 might bind extracellular oligonucleotides and/or oligosaccharides. It has been previously shown that the 280 OB-fold is able to bind G-quadruplex structures, but the relevance of this binding has yet to be determined 281 and it is conceivable that G-quadruplex binding mimics binding of its natural substrate as proposed earlier 
317
The growth was monitored by optical density reading at 600 nm (OD600).
318
All strains are described in Table 2. 319 320 Strain construction 321 All oligonucleotides from this study are listed in Table 3 . All PCRs were performed on 630Δerm To construct the expression constructs for the tcdC mutants, the tcdC gene (CD0664 from C. 327 difficile 630; GenBank accession no. YP_001087138.1) was amplified by PCR using primers oDB0071 and 328 oDB0072 from C. difficile chromosomal DNA. The PCR product was subsequently cloned into pCR2.1TOPO 329 (Invitrogen), according to manufacturer's instructions, to yield vector pCR2.1TcdC (Table 1) . The TcdC 330 fragment was amplified from pCR2.1TcdC with primers oDB0071 and oCDTcdCmyc3, which allows the 331 addition of a 3xmyc-tag at the C-terminus. The resulting PCR fragment was digested with SacI and BamHI 332 and ligated into pRPF185 digested with the same enzymes, to yield vector pLDJ1 (Table 2) 
334
Site-specific mutations were introduced in pCR2.1TcdC sequence via QuikChange mutagenesis 335 (Stratagene) . For the C51S mutation, primer set oCDTcdCC51SF/oCDTcdCC51SR was used. Addition of a 336 Myc-tag and cloning into pRPF185 was performed as described for the wild type protein, yielding pLDJ2 337 (Table 1) .
338
Vector pLDJ2, harbouring Ptet-tcdC(C51S)-3xmyc was used as template to generate the mutant 339 tcdC(C51S/S175C) via QuikChange mutagenesis (Stratagene) using the primer set 340 oCDTcdCS175CFW/oCDTcdCS175CREV, yielding pLDJ5 (Table 1) (Table 1) .
347
The tcdC gene was amplified by PCR with primer set oDB0071/oTcdCRev (Table 3) 
350
The srtB gene (CD2718 from C. difficile 630; GenBank accession no. YP_001089230.1) was 351 amplified from C. difficile genomic DNA with primers oCD-sortaseF/oCD-sortaseR (Table 3) , digested with 352 XhoI and SacI, and placed into similarly digested pAF302, yielding vector pAP233 (Table 1) 
362
Subsequently, the piece of blot was washed twice with TBST for 5 minutes. Then, the membrane was 363 soaked in acidic glycine buffer (100 mM glycine, pH 2,5) for 5 minutes and washed twice in TBST for 5 364 minutes. The blot was blocked in 10% ELK (in TBST) for 1 hour at room temperature. After washing it 365 twice with TBST for 5 minutes, the blot was incubated with 10 ml of 5 x diluted serum (in TBS) overnight 366 at 4 °C. Afterwards, the diluted serum was removed and the blot was washed 3 times with TBST for 5 367 minutes and 2 times with PBS for 5 minutes. The blot was incubated with 1 mL of acidic glycine buffer for Schrödinger, LLC. Both N-and C-terminus are marked in the figure. The C-terminal residues S175 (orange 470 stick) and C184 (red stick) are indicated. S175 is exposed on the protein surface and C184 is buried inside 471 the C-terminal OB-fold. 
